Conflicts of interest H Iznardo has perceived consultancy/speaker honoraria and/ or participated in clinical trials sponsored by Boehringer Ingelheim, Novartis, Pfizer and UCB. E Vilarrasa has perceived consultancy/speaker honoraria and/… Click to show full abstract
Conflicts of interest H Iznardo has perceived consultancy/speaker honoraria and/ or participated in clinical trials sponsored by Boehringer Ingelheim, Novartis, Pfizer and UCB. E Vilarrasa has perceived consultancy/speaker honoraria and/ or participated in clinical trials sponsored by AbbVie, Almirall, Boehringer, Celgene, Janssen, Leo Pharma, Eli Lilly, Merck, MSD, Novartis, Pfizer, Sanofi and UCB. E Ro e has perceived consultancy/speaker honoraria and/ or participated in clinical trials sponsored by Galderma and Pfizer. L. Puig has perceived consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, JS BIOCAD, Leo-Pharma, Eli Lilly and Co., Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB.
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!